Found: 20
Select item for more details and to access through your institution.
Forthcoming Meetings.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1614, doi. 10.1093/neuonc/noz210
- Publication type:
- Article
Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1540, doi. 10.1093/neuonc/noz116
- By:
- Publication type:
- Article
Highlights from the Literature.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1495, doi. 10.1093/neuonc/noz211
- By:
- Publication type:
- Article
A new chance for EGFR inhibition in glioblastoma?
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1487, doi. 10.1093/neuonc/noz196
- By:
- Publication type:
- Article
"Not all that glitters is gold": insights from the Far East and how to solve a conundrum.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1490, doi. 10.1093/neuonc/noz188
- By:
- Publication type:
- Article
Imaging biomarkers for brain metastases: more than meets the eye.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1493, doi. 10.1093/neuonc/noz193
- By:
- Publication type:
- Article
Tackling 1q+ PFA ependymomas.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1489, doi. 10.1093/neuonc/noz194
- By:
- Publication type:
- Article
Comment on "Hypometabolic gliomas on FET-PET—is there an inverted U-curve for survival?".
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1612, doi. 10.1093/neuonc/noz173
- By:
- Publication type:
- Article
The anticipated revision of the grading criteria for adult isocitrate dehydrogenase–mutant diffuse glioma within the neuro-oncology community.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1485, doi. 10.1093/neuonc/noz186
- By:
- Publication type:
- Article
The potential of cerebrospinal fluid–based liquid biopsy approaches in CNS tumors.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1509, doi. 10.1093/neuonc/noz156
- By:
- Publication type:
- Article
Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1610, doi. 10.1093/neuonc/noz157
- By:
- Publication type:
- Article
Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[<sup>18</sup>F]fluoroethyl)-L-tyrosine positron emission tomography (<sup>18</sup>F-FET PET).
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1595, doi. 10.1093/neuonc/noz166
- By:
- Publication type:
- Article
Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1607, doi. 10.1093/neuonc/noz145
- By:
- Publication type:
- Article
Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT Consortium.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1565, doi. 10.1093/neuonc/noz139
- By:
- Publication type:
- Article
Tumoricidal stem cell therapy enables killing in novel hybrid models of heterogeneous glioblastoma.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1552, doi. 10.1093/neuonc/noz138
- By:
- Publication type:
- Article
MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1578, doi. 10.1093/neuonc/noz141
- By:
- Publication type:
- Article
Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1587, doi. 10.1093/neuonc/noz131
- By:
- Publication type:
- Article
Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1529, doi. 10.1093/neuonc/noz127
- By:
- Publication type:
- Article
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1519, doi. 10.1093/neuonc/noz124
- By:
- Publication type:
- Article
The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.
- Published in:
- Neuro-Oncology, 2019, v. 21, n. 12, p. 1498, doi. 10.1093/neuonc/noz119
- By:
- Publication type:
- Article